文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

组成性激活MyD88/CD40共刺激增强靶向血液系统恶性肿瘤的CAR-T细胞扩增与疗效

Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
PubMed 文献 · Leukemia · 2019-02-28

该研究描述了一种新型CAR-T平台,通过低效2A连接子将TLR衔接分子MyD88和TNF家族成员CD40(MC)与CAR分子串联,提供组成性信号驱动CAR-T存活、增殖及抗CD19+和CD123+血液肿瘤活性。MC增强CAR-T在动物模型中活性增强伴恶病质和高人细胞因子水平,但可通过iC9安全开关、抗TNF-α中和抗体或选择低细胞因子产生的CD8+ T细胞解决毒性而不损失抗肿瘤活性。高基础活性对体内CAR-T扩增至关重要。

要点

  • MC共刺激信号通过低效2A连接子驱动CAR-T组成性信号,增强体内扩增与抗肿瘤活性。
  • MC增强CAR-T活性伴随恶病质和人细胞因子升高,可用iC9安全开关、抗TNF-α抗体或低细胞因子CD8+ T细胞控制。
  • 高基础活性是体内CAR-T扩增的关键。

核心结论

  • 利用MyD88和CD40信号元件及独特CAR-T结构可驱动T细胞体内增殖,增强CAR-T疗法。

研究设计与样本

  • 研究描述了一种新型CAR-T细胞平台,利用TLR衔接分子MyD88和TNF家族成员CD40(MC)通过低效2A连接子与CAR分子串联,针对CD19+和CD123+血液肿瘤。

主要发现

  • MC增强的CAR-T细胞在动物模型中显示强活性,伴随恶病质和高人细胞因子产生。
  • 毒性可通过iC9安全开关降低血清细胞因子、抗TNF-α中和抗体或选择低细胞因子产生的CD8+ T细胞解决,且不损失抗肿瘤活性。
  • 高基础活性对体内CAR-T扩增至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Successful adoptive chimeric antigen receptor (CAR) T-cell therapies against hematological malignancies require CAR-T expansion and durable persistence following infusion. Balancing increased CAR-T potency with safety, including severe cytokine-release syndrome (sCRS) and neurotoxicity, warrants inclusion of safety mechanisms to control in vivo CAR-T activity. Here, we describe a novel CAR-T cell platform that utilizes expression of the toll-like receptor (TLR) adaptor molecule, MyD88, and tumor-necrosis factor family member, CD40 (MC), tethered to the CAR molecule through an intentionally inefficient 2A linker system, providing a constitutive signal that drives CAR-T survival, proliferation, and antitumor activity against CD19+ and CD123+ hematological cancers. Robust activity of MC-enhanced CAR-T cells was associated with cachexia in animal models that corresponded with high levels of human cytokine production. However, toxicity could be successfully resolved by using the inducible caspase-9 (iC9) safety switch to reduce serum cytokines, by administration of a neutralizing antibody against TNF-α, or by selecting "low" cytokine-producing CD8+ T cells, without loss of antitumor activity. Interestingly, high basal activity was essential for in vivo CAR-T expansion. This study shows that co-opting novel signaling elements (i.e., MyD88 and CD40) and development of a unique CAR-T architecture can drive T-cell proliferation in vivo to enhance CAR-T therapies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Collinson-Pautz MR, Chang WC, Lu A, et al. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia. 2019. PMID: 30816327. doi:10.1038/s41375-019-0417-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。